Thiers B H
Department of Dermatology, Medical University of South Carolina, Charleston, USA.
J Am Acad Dermatol. 1997 Sep;37(3 Pt 2):S69-71.
Topical calcipotriene ointment has been approved for the treatment of plaque-type psoriasis.
This article explores the possible use of topical calcipotriene ointment in the treatment of nail and intertriginous psoriasis, palmoplantar and pustular psoriasis, Reiter's syndrome, pityriasis rubra pilaris, and disorders of keratinization.
The recent literature is reviewed.
Recent reports suggest that certain ichthyoses (particularly the hyperproliferative variants) and keratodermas may respond to topical calcipotriene ointment. The activity of calcipotriene relates to a dose-dependent decrease in proliferation and an increase in terminal differentiation of keratinocytes.
Patients with other disorders characterized by epidermal hyperproliferation may also be candidates for treatment. The use of calcipotriene in treating congenital hyperproliferative disorders is limited by the theoretical risk of hypercalcemia from absorption of the drug after application to extensive areas of skin.
外用卡泊三醇软膏已被批准用于治疗斑块型银屑病。
本文探讨外用卡泊三醇软膏在治疗甲部及间擦部位银屑病、掌跖脓疱型银屑病、赖特综合征、毛发红糠疹和角化异常性疾病中的可能应用。
回顾近期文献。
近期报告表明，某些鱼鳞病（尤其是增殖性变异型）和角化病可能对外用卡泊三醇软膏有反应。卡泊三醇的活性与角质形成细胞增殖的剂量依赖性降低和终末分化增加有关。
其他以表皮增殖为特征的疾病患者也可能是治疗对象。由于大面积皮肤应用该药后吸收导致高钙血症的理论风险，卡泊三醇在治疗先天性增殖性疾病中的应用受到限制。
